Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation
We previously reported clinical improvement, increase in putamen [18F]-dopa uptake on
PET imaging, and neuropathologic evidence of sprouting of dopaminergic fibers following
chronic intraputaminal delivery of glial cell line–derived neurotrophic factor (GDNF) in
idiopathic Parkinson disease (PD). 1–3 We now provide clinical and PET evidence of
persistent efficacy lasting for at least 3 years following cessation of GDNF infusion in a
patient with PD. This is a single-case observational study, providing Class IV evidence.
PET imaging, and neuropathologic evidence of sprouting of dopaminergic fibers following
chronic intraputaminal delivery of glial cell line–derived neurotrophic factor (GDNF) in
idiopathic Parkinson disease (PD). 1–3 We now provide clinical and PET evidence of
persistent efficacy lasting for at least 3 years following cessation of GDNF infusion in a
patient with PD. This is a single-case observational study, providing Class IV evidence.
We previously reported clinical improvement, increase in putamen [18F]-dopa uptake on PET imaging, and neuropathologic evidence of sprouting of dopaminergic fibers following chronic intraputaminal delivery of glial cell line–derived neurotrophic factor (GDNF) in idiopathic Parkinson disease (PD).1–3 We now provide clinical and PET evidence of persistent efficacy lasting for at least 3 years following cessation of GDNF infusion in a patient with PD. This is a single-case observational study, providing Class IV evidence.
American Academy of Neurology